🔗 Share this article

Given that the United States undertakes sweeping changes to its vaccine schedules, one figure appears in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning Covid vaccinations during the global health crisis and has concentrated on potential fatalities after Covid immunization in her recent position at the FDA.

Proposed Changes to Childhood Immunization Program

Agency leaders were set to reveal radical changes to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, it is understood – a substantial departure that would place the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A Shift at the FDA

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending some childhood immunization guidelines in the US so as to align more similar to Denmark, a country with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Qualifications

The appointee has little discernible background in pharmaceutical research, regulation or administrative roles, which has been standard for past heads of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She lacks background in industry regulation.”

Previous commissioners of CBER would “grasp legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Objectively, she lacks the sort of resume that prior appointees who led CBER have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those must be supervised,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the role, which supervises over 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” the former official concluded.

Response and Contentious Programs

When asked about inquiries about Høeg’s qualifications and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “questions are based on flawed presumptions”.

“This background aligns with the functions of her role,” the official explained, citing the months Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a disputed rapid medication authorization process that allegedly worried her predecessors. “By what process are these therapies being selected for this fast-track system? Who makes the choices?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent rules of all drugs, except for shots.”

Public Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if problematic, history, some experts said. She published a study using non-validated public submissions to assess the incidence of myocarditis following Covid immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Part of her “desired changes” for the current government included altering regulations for recently developed shots and discontinuing “non-essential” immunizations, she stated following the vote on a podcast. At the agency, Dr. Høeg has allegedly suggested excluding teenage boys from receiving COVID-19 vaccines.

“She is an complete ideologue who commences with her beliefs and reverse-engineers to retrofit the evidence in a highly disingenuous, untruthful manner,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|